ISSN: 2167-065X

Pharmacologie clinique et biopharmaceutique

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Thermosensitive Liposome Formulation with Topotecan and Doxorubicin as Drug Payload for Delivery Coupled with High Intensity Focused Ultrasound

Raafay Mehmood, Faran Rashid and Zainab Mansoor

The delivery of cancer drugs such as topotecan and doxorubicin poses risks such as off target tissue interactions and systemic toxicity. The use of thermosensitive liposomes provides a targeted manner to deliver such drugs with minimal risk, since drug release occurs upon administration of hyperthermia at the target site, such as focused ultrasound. Topotecan and doxorubicin were tested for their suitability in the design of a thermosensitive liposome formulation, using the film hydration method to produce thermosensitive liposomes. The lipid film was hydrated with ammonium sulphate buffer (300 mM pH 4.0), with subsequent gas extrusion. The exterior of the liposomes was adjusted to pH 7.4 with buffer followed by drug loading by incubation at 38°C. Differential scanning calorimetry, dynamic light scattering, and fluorescence measurements were carried out as characteristic tests. Thermosensitive liposomes with a TM of 46°C and an approximate diameter of 100nm were produced, while releasing their drug payload between 39°C-42°C. Doxorubicin ’ s self-quenching properties prevented accurate release profile fluorescence readings. Therefore, topotecan is a better suited model drug for the design and optimization of a thermosensitive liposome formulation compared to doxorubicin, reducing the risk of drug leakage outside of target site. Thermosensitive liposomes were successfully formulated with topotecan and doxorubicin.